



## **Axonics® to Report Second Quarter 2022 Financial Results on August 1**

July 11, 2022

IRVINE, Calif.--(BUSINESS WIRE)--Jul. 11, 2022-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1.

Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. Interested parties that would like to join the conference call by telephone are required to register in advance by visiting the following link: [Axonics 2Q22 registration](#). After registering, a confirmation email will be sent that includes the dial-in number and unique access code required to join the conference call by telephone.

For those not planning to ask a question on the conference call, the company recommends joining the live webcast, which can be accessed by visiting the following link: [Axonics 2Q22 webcast](#). A replay of the webcast will be available shortly after the conclusion of the conference call and will be archived in the [Events](#) section of the Axonics investor relations website.

### **About Axonics**

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 [Deloitte](#) Technology Fast 500™ and the 2022 [Financial Times](#) ranking of the 500 fastest growing companies in the Americas.

Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company's best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit [www.axonics.com](http://www.axonics.com).

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20220711005237/en/>

Neil Bhalodkar  
Investor Relations  
949-336-5293  
[ir@axonics.com](mailto:ir@axonics.com)

Source: Axonics, Inc.